ストックスクリーナーアプリを入手
0.041
141.18%
0.024
前日終値:
$0.017
開ける：
$0.05
24時間の取引高:
52,711
Relative Volume:
28.68
時価総額：
$N/A
収益：
-
当期純損益:
$149.05M
株価収益率:
0.0207
EPS:
1.9846
ネットキャッシュフロー:
$-6.05M
1週間 パフォーマンス:
+141.18%
1か月 パフォーマンス:
+141.18%
6か月 パフォーマンス:
+141.18%
1年 パフォーマンス:
-96.95%
1日の値動き範囲:
$0.041
$0.05
1週間の範囲:
$0.041
$0.05
52週間の値動き範囲:
$0.017
$0.05
Galera Therapeutics Inc Stock (GRTX) Company Profile
Compare GRTX vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.041 | 0 | 0 | 149.05M | -6.05M | 1.9846 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-10 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-10-19 | ダウングレード | BTIG Research | Buy → Neutral |
| 2021-10-19 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2019-12-02 | 開始されました | BTIG Research | Buy |
| 2019-12-02 | 開始されました | BofA/Merrill | Buy |
| 2019-12-02 | 開始されました | Citigroup | Buy |
| 2019-12-02 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Galera Therapeutics Inc (GRTX) 最新ニュース
Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia
Galera Sets Deadlines for 2026 Combined Annual Meeting - TipRanks
Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView
Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan
Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView
Galera Therapeutics (GRTX) exits radiotherapy, bets on pan-NOS breast cancer drug - Stock Titan
Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
GRTX (Galera Therapeutics) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MSN
GRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks
Galera Therapeutics (GRTX) grants board discretion on Series B conversion - Stock Titan
Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today
Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Intellectia AI
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Head to Head Analysis: Lite Strategy (NASDAQ:LITS) and Galera Therapeutics (NASDAQ:GRTX) - Defense World
GRTX (Galera Therapeutics) EV-to-OCF : 0.32 (As of Dec. 19, 2025) - GuruFocus
Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView
GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan
Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan
Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D - Citeline News & Insights
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet
Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent
Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
Galera Therapeutics Inc (GRTX) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):